Compare Alcon AG (ALC) vs Quantumscape Corp (QS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Quantumscape Corp — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Quantumscape Corp trades at $6.68 (market cap $4.18B). The key difference: Alcon AG is far larger — about 7.8× Quantumscape Corp's market cap, and Alcon AG pays a 0.54% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals.
| ALC | QS | |
|---|---|---|
Market Cap | $32.69B | $4.18B |
Sector | Health | Consumer Cyclical |
52-Week High | $92.22 | $18.44 |
52-Week Low | $62.02 | $5.96 |
Enterprise Value | $36.28B | $3.34B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
QuantumScape trades at $6.79, down 3.96% today, reflecting ongoing investor caution amid its pre-revenue development stage. The stock shows a bearish technical trend with negative cash flows and significant losses, though recent news of a joint research agreement with Honda (June 18, 2026) provides optimism for its solid-state battery technology. Analyst consensus is heavily weighted toward Hold (72.73%) with no Buy ratings, indicating skepticism about near-term commercialization prospects.
The outlook remains high-risk with substantial execution hurdles in battery development and commercialization. While partnerships like Honda offer long-term potential, persistent negative profitability and cash burn pose significant challenges. Investors should weigh the speculative nature against potential disruptive upside in the evolving EV battery market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
